Erdos, J. and Stanak, M. (2016): Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD). Decision Support Document 101.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

Grössmann, N. and Wolf, S. and Wild, C. (2021): Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). Decision Support Document 127.

Mad, P. (2007): [Photodynamic therapy in the palliative treatment of malignant oesophageal stenosis]. HTA-Newsletter 58: pp. 3-4.

Mad, P. and Wild, C. (2007): [Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract. HTA in hospitals]. Decision Support Document 03.

Nachtnebel, A (2015): Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma. DSD: Horizon Scanning in Oncology 54.

Riegelnegg, M. and Gassner, L. and Grössmann-Waniek, N. (2023): Robot-assisted surgery in thoracic and visceral indications – Update 2023. HTA-Projektbericht 108/ Update 2023.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Rothschedl, E. and Grössmann, N. (2023): Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC). Update February 2024. Fact Sheet Nr. 143.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Update April 2023. Oncology Fact Sheet Nr. 115.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with chemotherapy for the first-line treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 83.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 82.

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

Schmidt , L. and Lohr, P. and Prenner, A. and Poerio, E. and Ceresola, E. and Andretta, M. and Cavazzana, A. (2019): Robot-assisted surgery in thoracic and visceral indications. HTA-Projektbericht 108.

Stanak, M. and Hawlik, K. (2017): Electric stimulation therapy in patients with gastroesophageal reflux disease. Decision Support Document 104.

Strohmaier, C. and Erdos, J. (2022): Lower Esophageal Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD). Decision Support Document 134.

Wild, C. (2005): [Targeted therapies]. ITA-Newsletter September 2005: pp. 11-12.

Wild, C. (2004): [Photodynamic therapy/PDT]. HTA-Newsletter 27: p. 4.

Wild, C. (2002): [The EndoCinch suturing system]. HTA-Newsletter 06: pp. 3-4.

Wild, C. (2015): Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses. Decision Support Document 89.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Update February 2022. Oncology Fact Sheet Nr. 63.

Wolf, S. (2021): Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC). Update November 2021. Oncology Fact Sheet Nr. 59.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus. Update August 2021. Oncology Fact Sheet Nr. 54.